category
Nature Communications
date
Mar 25, 2026
slug
status
Published
summary
开发了基于结构工程的组蛋白H3竞争性LSD1抑制剂TAS1440,通过提高特异性并减少脱靶效应,在SCLC细胞中实现转录调控和表观遗传重编程,克服现有LSD1抑制剂的局限性。
tags
核酸蛋白工具酶
type
Post
📄 原文题目
LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC
🔗 原文链接
💡 AI 核心解读
开发了基于结构工程的组蛋白H3竞争性LSD1抑制剂TAS1440,通过提高特异性并减少脱靶效应,在SCLC细胞中实现转录调控和表观遗传重编程,克服现有LSD1抑制剂的局限性。
📝 英文原版摘要
<p>Nature Communications, Published online: 25 March 2026; <a href="https://www.nature.com/articles/s41467-026-70984-1">doi:10.1038/s41467-026-70984-1</a></p>Existing inhibitors for lysine-specific histone demethylase 1A (LSD1), a key driver for small cell lung cancer (SCLC) carcinogenesis, have notable limitations. Here, the authors employ structure-based engineering to develop a histone H3-competitive LSD1 inhibitor to enhance specificity and reduce off-target effects in SCLC cells through transcriptional regulation and epigenetic reprogramming.
- 作者:NotionNext
- 链接:https://tangly1024.com/article/32e48bd6-1f96-81a7-80f4-df0446ab6d93
- 声明:本文采用 CC BY-NC-SA 4.0 许可协议,转载请注明出处。
相关文章
